Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Continuously held since 2Q 2024, but saw tax-loss harvesting sales during the quarter. The manager remains...
— David Polansky
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on PAR Technology Corporation
PAR Technology grew ARR by 102% in 2024 to $276 million through 22% organic expansion and key acquisitions. Achieving positive EBITDA...
PAR Technology was also a detractor despite continued solid underlying performance.
Par Technology has struggled due to POS rollout delays, industry pessimism, and questionable capital allocation decisions. Although the manager...
More institutional theses from Immersion Investment Partners
Mama's Creations (MAMA – Doubted Champion) We have written about our investment in Mama's Creations almost ad nauseam.
Red Violet (RDVT – Underdog) merits some discussion, given the violent contraction in the first quarter and the subsequent snapback.
Strata Critical Medical is a newer holding for the partnership, having been purchased in September 2025.